amitriptyline has been researched along with Sclerosis, Systemic in 1 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bondavalli, P | 1 |
| Parodi, A | 1 |
| Rebora, A | 1 |
1 other study available for amitriptyline and Sclerosis, Systemic
| Article | Year |
|---|---|
Peripheral neuropathy in scleroderma successfully treated with amitriptyline.
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Female; Humans; Middle Aged; Peripheral Nervous Sys | 1997 |